G1 Therapeutics announced that the Company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
- G1 Therapeutics price target lowered to $6 from $12 at Needham
- G1 Therapeutics price target lowered to $3 from $9 at H.C. Wainwright
- G1 Therapeutics Reports Setback in Phase 3 Cancer Trial
- G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)